{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T15:51:09Z","timestamp":1783785069840,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:00:00Z","timestamp":1579219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:00:00Z","timestamp":1579219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Magnetic resonance imaging (MRI) and ultrasound (US) fusion prostate-biopsies can be performed in a transrectal (TR-fusion) or transperineal (TP-fusion) approach. Prospective comparative evidence is limited. In this study we compared the detection rate of clinically-significant prostate-cancer (csPCa) within an index lesion between TR and TP-fusion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>This was a prospective, noninferiority, and within-person trial. Men scheduled for MRI\u2013US-fusion with a discrete MRI PI-RRAD\u2009\u2265\u20093 lesion were included. A dominant index lesion was determined for each subject and sampled by TR and TP-fusion during the same session. The order of biopsies was randomized and equipment was reset to avoid chronological and incorporation bias. For each subject, the index lesion was sampled 4\u20136 times in each approach. All biopsies were performed using Navigo fusion software (UC-Care, Yokneam, Israel). csPCa was defined as: Grade Group\u2009\u2265\u20092 or cancer-core length\u2009\u2265\u20096\u2009mm. We used a noninferiority margin of 10% and a one-sided alpha level of 5%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seventy-seven patients completed the protocol. Median age was 68.2 years (IQR:64.2\u201372.2), median PSA was 8.9\u2009ng\/ml (IQR:6.18\u201312.2). Ten patients (13%) were biopsy naive, others (87%) had a previous biopsy. csPCa was detected in 32 patients (42%). All of these cases were detected by TP-fusion, while only 20 (26%) by TR-fusion. Absolute difference for csPCa diagnosis was 15.6 (CI 90% 27.9\u20133.2%) in favor of TP-fusion (<jats:italic>p<\/jats:italic>\u2009=\u20090.029). TP-fusion was noninferior to TR-fusion. The lower boundary of the 90% confidence-interval between TP-fusion and TR-fusion was greater than zero, therefore TP-fusion was also found to be superior. Exploratory subgroup analyses showed TP-fusion was consistently associated with higher detection rates of csPCa compared with TR-fusion in patient and index-lesion derived subgroups (size, location, PI-RADS, PSA, and biopsy history).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In this study, TP-fusion biopsies were found to be noninferior and superior to TR-fusion biopsies in detecting csPCa within MRI-visible index lesion. Centers experienced in both TP and TR-fusion should consider these results when choosing biopsy method.<\/jats:p><\/jats:sec>","DOI":"10.1038\/s41391-020-0205-7","type":"journal-article","created":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T13:02:26Z","timestamp":1579266146000},"page":"449-456","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["A noninferiority within-person study comparing the accuracy of transperineal to transrectal MRI\u2013US fusion biopsy for prostate-cancer detection"],"prefix":"10.1038","volume":"23","author":[{"given":"Yaara","family":"Ber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niv","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomit","family":"Tamir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Benjaminov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim","family":"Yakimov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivan","family":"Sela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6331-5056","authenticated-orcid":false,"given":"Daniel","family":"Halstauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Baniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kedar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Margel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,17]]},"reference":[{"key":"205_CR1","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","volume":"389","author":"HU Ahmed","year":"2017","unstructured":"Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389:815\u201322.","journal-title":"Lancet."},{"key":"205_CR2","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378:1767\u201377.","journal-title":"N Engl J Med"},{"key":"205_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.juro.2014.07.086","volume":"193","author":"F Bruy\u00e8re","year":"2015","unstructured":"Bruy\u00e8re F, Malavaud S, Bertrand P, Decock A, Cariou G, Doublet JD, et al. Prosbiotate: a multicenter, prospective analysis of infectious complications after prostate biopsy. J Urol. 2015;193:145\u201350.","journal-title":"J Urol."},{"key":"205_CR4","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/bju.12536","volume":"114","author":"JP Grummet","year":"2014","unstructured":"Grummet JP, Weerakoon M, Huang S, Lawrentschuk N, Frydenberg M, Moon DA, et al. Sepsis and \u2018superbugs\u2019: should we favour the transperineal over the transrectal approach for prostate biopsy? BJU Int. 2014;114:384\u20138.","journal-title":"BJU Int"},{"key":"205_CR5","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/S0090-4295(02)02551-7","volume":"61","author":"P Emiliozzi","year":"2003","unstructured":"Emiliozzi P, Corsetti A, Tassi B, Federico G, Martini M, Pansadoro V. Best approach for prostate cancer detection: a prospective study on transperineal versus transrectal six-core prostate biopsy. Urology. 2003;61:961\u20136.","journal-title":"Urology."},{"key":"205_CR6","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1111\/j.1464-410X.2012.10972.x","volume":"110","author":"NJ Mabjeesh","year":"2012","unstructured":"Mabjeesh NJ, Lidawi G, Chen J, German L, Matzkin H. High detection rate of significant prostate tumors in anterior zones using transperineal ultrasound-guided template saturation biopsy. BJU Int. 2012;110:993\u20137.","journal-title":"BJU Int"},{"key":"205_CR7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/sj.pcan.4500985","volume":"11","author":"A Takenaka","year":"2008","unstructured":"Takenaka A, Hara R, Ishimura T, Fujii T, Jo Y, Nagai A, et al. A prospective randomized comparison of diagnostic efficacy between transperineal and transrectal 12-core prostate biopsy. Prostate Cancer Prostatic Dis. 2008;11:134\u20138.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"205_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12957-019-1573-0","volume":"17","author":"J Xiang","year":"2019","unstructured":"Xiang J, Yan H, Li J, Wang X, Chen H, Zheng X. Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis. World J Surg Oncol. 2019;17:31.","journal-title":"World J Surg Oncol"},{"key":"205_CR9","doi-asserted-by":"publisher","first-page":"23322","DOI":"10.18632\/oncotarget.15056","volume":"8","author":"J Xue","year":"2017","unstructured":"Xue J, Qin Z, Cai H, Zhang C, Li X, Xu W, et al. Comparison between transrectal and transperineal prostate biopsy for detection of prostate cancer: a meta-analysis and trial sequential analysis. Oncotarget. 2017;8:23322\u201336.","journal-title":"Oncotarget."},{"key":"205_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.eururo.2015.08.052","volume":"69","author":"JC Weinreb","year":"2016","unstructured":"Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS prostate imaging\u2014reporting and data system: 2015, version 2. Eur Urol. 2016;69:16\u201340.","journal-title":"Eur Urol"},{"key":"205_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4682-7-23","volume":"7","author":"G Kepner","year":"2010","unstructured":"Kepner G, Kepner J. Transperineal biopsy: analysis of a uniform core sampling pattern that yields data on tumor volume limits in negative biopsies. Theor Biol Med Model. 2010;7:23.","journal-title":"Theor Biol Med Model"},{"key":"205_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.juro.2010.08.082","volume":"185","author":"T Wolters","year":"2011","unstructured":"Wolters T, Roobol MJ, van Leeuwen P, van den Bergh RC, Hoedemaeker RF, van Leenders GJ, et al. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a random screening trial. J Urol. 2011;185:121\u201325.","journal-title":"J Urol"},{"key":"205_CR13","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/1097-0142(19930201)71:3+<933::AID-CNCR2820711408>3.0.CO;2-L","volume":"71","author":"T Stamey","year":"1993","unstructured":"Stamey T, Freiha F, McNeal J, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer. 1993;71:933\u201338.","journal-title":"Cancer"},{"key":"205_CR14","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.juro.2011.03.147","volume":"186","author":"HU Ahmed","year":"2011","unstructured":"Ahmed HU, Hu Y, Carter T, Arumainayagam N, Lecornet E, Freeman A, et al. Characterizing clinically significant prostate cancer using template prostate mapping biopsy. J Urol. 2011;186:458\u201364.","journal-title":"J Urol"},{"key":"205_CR15","unstructured":"Evans S, Royston P, Day S. Minim: allocation by minimisation in clinical trials (ver 1.5). http:\/\/www-users.york.ac.uk\/~mb55\/guide\/minim.htm. Accessed 27 Sep 2018."},{"key":"205_CR16","doi-asserted-by":"crossref","unstructured":"Halstuch D, Baniel J, Lifshitz D, Sela S, Ber Y, Margel D. Characterizing the learning curve of MRI\u2013US fusion prostate biopsies. Prostate Cancer Prostatic Dis. 2019;22:546\u201351.","DOI":"10.1038\/s41391-019-0137-2"},{"key":"205_CR17","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1089\/end.2017.0694","volume":"32","author":"D Halstuch","year":"2018","unstructured":"Halstuch D, Baniel J, Lifshitz D, Sela S, Ber Y, Margel D. Assessment of needle tip deflection during transrectal guided prostate biopsy: implications for targeted biopsies. J Endourol. 2018;32:252\u20136.","journal-title":"J Endourol."},{"key":"205_CR18","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.eururo.2016.12.006","volume":"71","author":"MG Schouten","year":"2017","unstructured":"Schouten MG, van der Leest M, Pokorny M, Hoogenboom M, Barentsz JO, Thompson LC, et al. Why and where do we miss significant prostate cancer with multi-parametric magnetic resonance imaging followed by magnetic resonance-guided and transrectal ultrasound-guided biopsy in biopsy-na\u00efve men? Eur Urol. 2017;71:896\u2013903.","journal-title":"Eur Urol."},{"key":"205_CR19","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.eururo.2017.01.010","volume":"71","author":"G Giannarini","year":"2017","unstructured":"Giannarini G, Crestani A, Rossanese M, Ficarra V. Multiparametric magnetic resonance imaging targeted biopsy for early detection of prostate cancer: all that glitters is not gold! Eur Urol. 2017;71:904\u20136.","journal-title":"Eur Urol."},{"key":"205_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5124-9","volume":"18","author":"Z Mai","year":"2018","unstructured":"Mai Z, Zhou Z, Yan W, Xiao Y, Zhou Y, Liang Z, et al. The transverse and vertical distribution of prostate cancer in biopsy and radical prostatectomy specimens. BMC Cancer. 2018;18:1205.","journal-title":"BMC Cancer."},{"key":"205_CR21","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/bjc.2017.171","volume":"117","author":"K Cyll","year":"2017","unstructured":"Cyll K, Ersv\u00e6r E, Vlatkovic L, Pradhan M, Kildal W, Avranden Kj\u00e6r M, et al. Tumour heterogeneity poses a significant challenge to cancer biomarker research. Br J Cancer. 2017;117:367\u201375.","journal-title":"Br J Cancer"},{"key":"205_CR22","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.euo.2018.02.002","volume":"1","author":"A Stabile","year":"2018","unstructured":"Stabile A, Dell\u2019Oglio P, Gandaglia G, Fossati N, Brembilla G, Cristel G, et al. Not all multiparametric magnetic resonance imaging\u2013targeted biopsies are equal: the impact of the type of approach and operator expertise on the detection of clinically significant prostate cancer. Eur Urol Oncol. 2018;1:120\u20138.","journal-title":"Eur Urol Oncol"},{"key":"205_CR23","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/j.clgc.2016.07.007","volume":"15","author":"P Pepe","year":"2017","unstructured":"Pepe P, Garufi A, Priolo G, Pennisi M. Transperineal versus transrectal MRI\/TRUS fusion targeted biopsy: detection rate of clinically significant prostate cancer. Clin Genitourin Cancer. 2017;15:e33\u20136.","journal-title":"Clin Genitourin Cancer"},{"key":"205_CR24","doi-asserted-by":"publisher","first-page":"2176471","DOI":"10.1155\/2017\/2176471","volume":"2017","author":"S Tewes","year":"2017","unstructured":"Tewes S, Peters I, Tiemeyer A, Peperhove M, Hartung D, Pertschy S, et al. Evaluation of MRI\/ultrasound fusion-guided prostate biopsy using transrectal and transperineal approaches. Biomed Res Int. 2017;2017:2176471.","journal-title":"Biomed Res Int"},{"key":"205_CR25","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.eururo.2018.08.007","volume":"75","author":"S Hamid","year":"2019","unstructured":"Hamid S, Donaldson IA, Hu Y, Rodell R, Villarini B, Bonmati E, et al. The smarttarget biopsy trial: a prospective, within-person randomised, blinded trial comparing the accuracy of visual-registration and magnetic resonance imaging\/ultrasound image-fusion targeted biopsies for prostate cancer risk stratification. Eur Urol. 2019;75:733\u201340.","journal-title":"Eur Urol."},{"key":"205_CR26","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2018.11.040","volume":"75","author":"O Wegelin","year":"2019","unstructured":"Wegelin O, Exterkate L, van der Leest, Kummer JA, Vreuls W, de Bruin PC, et al. The FUTURE trial: a multicenter randomised controlled trial on target biopsy techniques based on magnetic resonance imaging in the diagnosis of prostate cancer in patients with prior negative biopsies. Eur Urol. 2019;75:582\u201390.","journal-title":"Eur Urol."},{"key":"205_CR27","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/iju.12634","volume":"22","author":"E Anastasiadis","year":"2015","unstructured":"Anastasiadis E, van der Meulen J, Emberton M. Hospital admissions after transrectal ultrasound-guided biopsy of the prostate in men diagnosed with prostate cancer: a database analysis in England. Int J Urol. 2015;22:181\u20136.","journal-title":"Int J Urol"},{"key":"205_CR28","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.eururo.2012.04.044","volume":"62","author":"A Carignan","year":"2012","unstructured":"Carignan A, Roussy J-F, Lapointe V, Valiquette L, Sabbagh R, P\u00e9pin J. Increasing risk of infectious complications after transrectal ultrasound-guided prostate biopsies: time to reassess antimicrobial prophylaxis? Eur Urol. 2012;62:453\u20139.","journal-title":"Eur Urol"},{"key":"205_CR29","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1097\/JU.0000000000000156","volume":"201","author":"V Stefanova","year":"2019","unstructured":"Stefanova V, Buckley R, Flax S, Spevack L, Hajek D, Tunis A, et al. Transperineal prostate biopsies using local anesthesia: experience with 1287 patients. Prostate cancer detection rate, complications and patient tolerability. J Urol. 2019;201:1121\u20136.","journal-title":"J Urol"},{"key":"205_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.urology.2012.01.061","volume":"80","author":"M Rom","year":"2012","unstructured":"Rom M, Pycha A, Wiunig C, Reissigl A, Waldert M, Klatte T, et al. Prospective randomized multicenter study comparing prostate cancer detection rates of end-fire and side-fire transrectal ultrasound probe configuration. Urology. 2012;80:15\u20138.","journal-title":"Urology."}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41391-020-0205-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-020-0205-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-020-0205-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T08:02:43Z","timestamp":1722326563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-020-0205-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,17]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["205"],"URL":"https:\/\/doi.org\/10.1038\/s41391-020-0205-7","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,17]]},"assertion":[{"value":"3 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}